Literature DB >> 17088486

Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.

William W Hope1, George L Drusano, Caroline B Moore, Andrew Sharp, Arnold Louie, Thomas J Walsh, David W Denning, Peter A Warn.   

Abstract

Disseminated candidiasis is associated with a high rate of morbidity and mortality. The presence of neutrophils and the timely administration of antifungal agents are likely to be critical factors for a favorable therapeutic outcome of this syndrome. The effect of neutropenia on the temporal profile of the burden of Candida albicans in untreated mice and those treated with amphotericin B was determined using a pharmacodynamic model of disseminated candidiasis. A mathematical model was developed to describe the rate and extent of the C. albicans killing attributable to neutrophils and to amphotericin B. The consequences of a delay in the administration of amphotericin B, flucytosine, or micafungin were studied by defining dose-response relationships. Neutrophils caused a logarithmic decline in fungal burden in treated and untreated mice. The combination of amphotericin B and neutrophils resulted in a high rate of Candida killing and a sustained anti-C. albicans effect. In neutropenic mice, 5 mg/kg of body weight of amphotericin B was required to prevent progressive logarithmic growth. An increased delay in drug administration resulted in a reduction in the maximum effect to a point at which no drug effect could be observed. Neutrophils and the timely initiation of antifungal agents are critical determinants in the treatment of experimental disseminated candidiasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17088486      PMCID: PMC1797682          DOI: 10.1128/AAC.00601-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Clinical manifestations and molecular epidemiology of late recurrent candidemia, and implications for management.

Authors:  C J Clancy; F Barchiesi; L Falconi DiFrancesco; A J Morris; D R Snydman; V L Yu; G Scalise; M H Nguyen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-08       Impact factor: 3.267

Review 2.  In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.

Authors:  David Andes
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

3.  Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation.

Authors:  T H Price; R A Bowden; M Boeckh; J Bux; K Nelson; W C Liles; D C Dale
Journal:  Blood       Date:  2000-06-01       Impact factor: 22.113

4.  Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use.

Authors:  W Hope; A Morton; D P Eisen
Journal:  J Hosp Infect       Date:  2002-01       Impact factor: 3.926

5.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

Authors:  G P Bodey; M Buckley; Y S Sathe; E J Freireich
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

6.  Hospital-acquired candidemia. The attributable mortality and excess length of stay.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1988-12

7.  Analysis of factors related to the occurrence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow transplant setting: a follow-up study.

Authors:  S Sallah; J Y Wan; N P Nguyen; P Vos; G Sigounas
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

8.  Risk factors for breakthrough candidemia.

Authors:  M Nucci; A L Colombo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-03-19       Impact factor: 3.267

9.  Attributable mortality of nosocomial candidemia, revisited.

Authors:  Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen Herwaldt; Michael Pfaller; Daniel Diekema
Journal:  Clin Infect Dis       Date:  2003-10-08       Impact factor: 9.079

10.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

View more
  15 in total

1.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

2.  Cholic Acid-Peptide Conjugates as Potent Antimicrobials against Interkingdom Polymicrobial Biofilms.

Authors:  Siddhi Gupta; Jyoti Thakur; Sanjay Pal; Ragini Gupta; Deepakkumar Mishra; Sandeep Kumar; Kavita Yadav; Amandeep Saini; Prabhu S Yavvari; Madhukar Vedantham; Archana Singh; Aasheesh Srivastava; Rajendra Prasad; Avinash Bajaj
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 3.  Candida albicans-endothelial cell interactions: a key step in the pathogenesis of systemic candidiasis.

Authors:  Sarah E W Grubb; Craig Murdoch; Peter E Sudbery; Stephen P Saville; Jose L Lopez-Ribot; Martin H Thornhill
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

4.  Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.

Authors:  Jodi M Lestner; Susan J Howard; Joanne Goodwin; Lea Gregson; Jayesh Majithiya; Thomas J Walsh; Gerard M Jensen; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

5.  Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.

Authors:  Susan J Howard; Joanne Livermore; Andrew Sharp; Joanne Goodwin; Lea Gregson; A Alastruey-Izquierdo; D S Perlin; Peter A Warn; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

6.  In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Johan W Mouton; Willem J G Melchers; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

7.  Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model.

Authors:  G L Drusano; Christine Fregeau; Weiguo Liu; D L Brown; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

8.  Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Authors:  Jürgen B Bulitta; Neang S Ly; Jenny C Yang; Alan Forrest; William J Jusko; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

9.  Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.

Authors:  Peter A Warn; Andrew Sharp; Arvind Parmar; Jayesh Majithiya; David W Denning; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

10.  Implications of the EUCAST Trailing Phenomenon in Candida tropicalis for the In Vivo Susceptibility in Invertebrate and Murine Models.

Authors:  K M T Astvad; D Sanglard; E Delarze; R K Hare; M C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.